Pharm & Bio> Details
20 Minutes delay
- Share Prices
Price-sensitive announcements are indicated in red/hot pink colour.
|Company Name||MESOBLAST LIMITED|
|Official Listing Date||2004-12-16|
Mesoblast is a company focused on developing innovative cellular medicines. The company has established a portfolio of cell-based products with three programs in active Phase 3 clinical studies. Its product candidates under investigation are: MPC-150-IM（for chronic heart failure） 、 MPC-06-ID（ for chronic low back pain due to disc degeneration）、
MSC-100-IV（for acute graft versus host disease） and MPC-300-IV( for biologic refractory rheumatoid arthritis and diabetic nephropathy).
Mesoblast was publically listed on the Australian Securities Exchange (ASX:MSB) in December 2004. The Company has a Level 3 American Depositary Receipt program facility and listed on Nasdaq (Nasdaq: MESO) in November 2015.